The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.
Research has demonstrated an association between the gut microbiome composition and response to treatment with immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.
Real-world study data show that a high proportion of patients with metastatic clear cell renal cell carcinoma gain clinical benefit from treatment with cabozantinib following progression with immune checkpoint inhibitors.
A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.
The combination of nivolumab and ipilimumab demonstrates antitumor activity and acceptable toxicity in patients with metastatic renal cell carcinoma previously exposed to PD-1 or PD-L1 inhibitors, say the authors of a chart review.